Inactivation of viruses in red cell and platelet concentrates with aluminum phthalocyanine (AIPc) sulfonates.
Aluminum phthalocyanine tetrasulfonates (AIPcS) are photoactive compounds with absorption maxima at 665-675 nm. The inactivation of viruses (vesicular stomatitis virus, VSV; human immunodeficiency virus, HIV) added to either whole blood or red blood cell concentrates (RBCC) and platelet concentrates (PC) on treatment with tetrasulfonated AIPc (AIPcS4) was evaluated. Treatment of RBCC with 10 microM AIPcS4 and 44 J/cm2 visible light resulted in the inactivation of greater than or equal to 10(5.5) infectious doses (TCID50) of cell-free VSV, greater than or equal to 10(5.6) TCID50 of cell-associated VSV, and greater than or equal to 10(4.7) TCID50 of cell-free sindbis virus. Both greater than or equal to 10(4.2) TCID50 of cell-free and greater than or equal to 10(3.6) TCID50 of cell-associated forms of HIV were also shown to be inactivated. Encephalomyocarditis virus, used as a model for nonenveloped viruses, was not inactivated. Equivalent virus kill with Photofrin II required a substantially higher concentration of dye and longer exposure to visible light. Following AIPcS4 treatment, red cell integrity was well maintained as judged by the low level (less than 2%) of hemoglobin release immediately following treatment and on subsequent storage, by measurements of erythrocyte osmotic fragility, and by the normal recovery and circulatory survival on infusion of treated, autologous red blood cells in baboons. Treatment of PC with 10 microM AIPcS4 and 44 J/cm2 visible light also resulted in effective virus kill (greater than or equal to 10(5.5) TCID50) of VSV; however, both the rate and extent of platelet aggregation in response to collagen addition declined by at least 50%. Based on these results, further characterization of AIPcS4-treated RBCC is justified.
Horowitz
B
B
New York Blood Center, New York 10021.
Rywkin
S
S
Margolis-Nunno
H
H
Williams
B
B
Geacintov
N
N
Prince
A M
AM
Pascual
D
D
Ragno
G
G
Valeri
C R
CR
Huima-Byron
T
T
D000818:Animals; D016913:Blood Component Transfusion; D001792:Blood Platelets / Q000187:drug effects / Q000382:microbiology* / Q000528:radiation effects; D017707:Erythrocyte Transfusion; D004912:Erythrocytes / Q000187:drug effects / Q000382:microbiology* / Q000528:radiation effects; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology / Q000528:radiation effects; D006801:Humans; D007211:Indoles / Q000494:pharmacology* / Q000528:radiation effects; D009942:Organometallic Compounds / Q000494:pharmacology* / Q000528:radiation effects; D010215:Papio / Q000097:blood / Q000382:microbiology; D010777:Photochemistry; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology* / Q000528:radiation effects; D018406:Virus Physiological Phenomena; D014779:Virus Replication / Q000187:drug effects / Q000528:radiation effects; D014780:Viruses / Q000187:drug effects* / Q000528:radiation effects
D007211:Indoles; D009942:Organometallic Compounds; D011838:Radiation-Sensitizing Agents; C048577:aluminum tetrasulfophthalocyanine